Company Encyclopedia
View More
name
Clearside Biomedical
CLSD.US
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc.
4.514 T
CLSD.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking180/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE58.59%A
    • Profit Margin-780.90%E
    • Gross Margin100.00%A
  • Growth ScoreE
    • Revenue YoY-56.78%E
    • Net Profit YoY18.45%B
    • Total Assets YoY-60.08%E
    • Net Assets YoY-55.08%E
  • Cash ScoreE
    • Cash Flow Margin-12.81%D
    • OCF YoY-56.78%E
  • Operating ScoreD
    • Turnover0.16D
  • Debt ScoreE
    • Gearing Ratio563.45%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Clearside Biomedical shares are trading lower after the company recently announced it filed a voluntary petition for bankruptcy.

    benzinga_article·
    US
    CLSD
    0.00%
    benzinga_article·
    US
    CLSD
    0.00%

    Morning News Wrap-Up: Monday's Biggest Stock Market Stories!

    Monday's stock market highlights include Clearside Biomedical's stock plummeting due to a bankruptcy filing, Inspire Veterinary Partners' stock surging despite a delisting notice, and Novo Nordisk's stock dropping after a failed Alzheimer's drug trial. Other notable movements include Alibaba's stock rise with an AI app update, Amazon's stock increase despite a police raid, and Tesla's stock boost after an analyst endorsement. Additionally, the Dow Jones rose with AI benefits, and Microsoft plans a second Xbox price hike.

    Tip Ranks·
    US
    NVO
    +0.88%
    US
    CLSD
    0.00%
    US
    CLSDQ
    -5.26%
    Tip Ranks·
    US
    NVO
    +0.88%
    US
    CLSD
    0.00%
    US
    CLSDQ
    -5.26%

    Clearside Biomedical shares are trading lower after the company announced it filed a voluntary petition for bankruptcy.

    benzinga_article·
    US
    CLSD
    0.00%
    benzinga_article·
    US
    CLSD
    0.00%

    Why Is Clearside Biomedical Stock (CLSD) Down Today?

    Clearside Biomedical (CLSD) stock dropped significantly after the company announced its voluntary Chapter 11 bankruptcy filing. The decision was made by the Board of Directors after evaluating strategic options. Clearside plans to sell its assets during the bankruptcy process and has requested to continue operations. The stock fell 70.59% in pre-market trading, with heavy trading activity noted.

    Tip Ranks·
    US
    CLSD
    0.00%
    US
    CLSDQ
    -5.26%
    Tip Ranks·
    US
    CLSD
    0.00%
    US
    CLSDQ
    -5.26%

    Clearside Biomedical Files For Chapter 11 Bankruptcy In US - Court Filing

    CLEARSIDE BIOMEDICAL FILES FOR CHAPTER 11 BANKRUPTCY IN US - COURT FILINGCLEARSIDE BIOMEDICAL LISTS ESTIMATED ASSETS IN RANGE OF $1 MILLION-$10 MILLION, ESTIMATED LIABILITIES IN RANGE OF $50 MILLION-$100 MILLION- COURT FILINGSource:

    Reuters·
    US
    CLSD
    0.00%
    US
    CLSDQ
    -5.26%
    Reuters·
    US
    CLSD
    0.00%
    US
    CLSDQ
    -5.26%
    © 2025 Longbridge｜Disclaimer